Tobias Täger1, Clara Wiebalck1, Hanna Fröhlich1, Anna Corletto1, Hugo A Katus1, Lutz Frankenstein2. 1. Department of Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 2. Department of Cardiology, Angiology, and Pulmonology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. lutz.frankenstein@med.uni-heidelberg.de.
Abstract
BACKGROUND: Extracellular matrix (ECM) biomarkers such as matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are pathophysiological key, prognostic marker and therapeutic target in chronic heart failure (HF). Serial measurements of MMPs and TIMPs may be useful for guidance of these applications. However, interpretation of time-dependent changes requires knowledge about the biological variation of ECM biomarkers. METHODS: We performed measurements of MMP-2, MMP-9, TIMP-1, and TIMP-4 in 50 patients with chronic HF who met rigid criteria for clinical stability at 3-h, 6-h, 1-week and 2-week time intervals. In addition, clinical and haemodynamic assessment was performed at baseline, at 1- and 2-week intervals. Haemodynamic variables were measured using inert gas rebreathing and impedance cardiography. Heart rhythm was monitored with external ECG event recorders throughout the complete study. Reference change values (RCVs) and minimal important differences (MIDs) were determined for MMP-2, MMP-9, TIMP-1, and TIMP-4. RESULTS: Clinical and haemodynamic variables were stable over time. Depending on the time-interval, RCVs ranged between 4.9 and 11.7% for MMP-2, 26.4 and 56.7% for MMP-9, 10.8 and 30.7% for TIMP-1, and 16.0 and 47.4% for TIMP-4, respectively. The MIDs varied between 43.38 and 65.22 ng/ml for MMP-2, 28.71 and 40.96 ng/ml for MMP-9, 52.32 and 156.07 ng/ml for TIMP-1, and 293.92 and 798.04 pg/ml for TIMP-4, respectively. CONCLUSION: The biological variation of ECM biomarkers differs with respect to individual biomarkers and time intervals. MMP-2 may be most suitable for serial biomarker measurements, as the biological variation is low irrespective of the time interval between measurements.
BACKGROUND: Extracellular matrix (ECM) biomarkers such as matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are pathophysiological key, prognostic marker and therapeutic target in chronic heart failure (HF). Serial measurements of MMPs and TIMPs may be useful for guidance of these applications. However, interpretation of time-dependent changes requires knowledge about the biological variation of ECM biomarkers. METHODS: We performed measurements of MMP-2, MMP-9, TIMP-1, and TIMP-4 in 50 patients with chronic HF who met rigid criteria for clinical stability at 3-h, 6-h, 1-week and 2-week time intervals. In addition, clinical and haemodynamic assessment was performed at baseline, at 1- and 2-week intervals. Haemodynamic variables were measured using inert gas rebreathing and impedance cardiography. Heart rhythm was monitored with external ECG event recorders throughout the complete study. Reference change values (RCVs) and minimal important differences (MIDs) were determined for MMP-2, MMP-9, TIMP-1, and TIMP-4. RESULTS: Clinical and haemodynamic variables were stable over time. Depending on the time-interval, RCVs ranged between 4.9 and 11.7% for MMP-2, 26.4 and 56.7% for MMP-9, 10.8 and 30.7% for TIMP-1, and 16.0 and 47.4% for TIMP-4, respectively. The MIDs varied between 43.38 and 65.22 ng/ml for MMP-2, 28.71 and 40.96 ng/ml for MMP-9, 52.32 and 156.07 ng/ml for TIMP-1, and 293.92 and 798.04 pg/ml for TIMP-4, respectively. CONCLUSION: The biological variation of ECM biomarkers differs with respect to individual biomarkers and time intervals. MMP-2 may be most suitable for serial biomarker measurements, as the biological variation is low irrespective of the time interval between measurements.
Authors: Michael R Zile; Pardeep S Jhund; Catalin F Baicu; Brian L Claggett; Burkert Pieske; Adriaan A Voors; Margaret F Prescott; Victor Shi; Martin Lefkowitz; John J V McMurray; Scott D Solomon Journal: Circ Heart Fail Date: 2016-01 Impact factor: 8.790
Authors: Patrick Collier; Chris J Watson; Victor Voon; Dermot Phelan; Aftab Jan; George Mak; Ramon Martos; John A Baugh; Mark T Ledwidge; Kenneth M McDonald Journal: Eur J Heart Fail Date: 2011-06-30 Impact factor: 15.534
Authors: Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg Journal: Eur Heart J Date: 2008-09-17 Impact factor: 29.983
Authors: João Pedro Ferreira; Mário Santos; José Carlos Oliveira; Irene Marques; Paulo Bettencourt; Henrique Carvalho Journal: Arq Bras Cardiol Date: 2015-01-23 Impact factor: 2.000
Authors: Tobias Täger; Hanna Fröhlich; Jennifer Franke; Karen Slottje; Andrea Horsch; Dietmar Zdunek; Georg Hess; Andreas Dösch; Hugo A Katus; Frank H Wians; Lutz Frankenstein Journal: ESC Heart Fail Date: 2015-06-15
Authors: Elke Bouwens; Milos Brankovic; Henk Mouthaan; Sara Baart; Dimitris Rizopoulos; Nick van Boven; Kadir Caliskan; Olivier Manintveld; Tjeerd Germans; Jan van Ramshorst; Victor Umans; K Martijn Akkerhuis; Isabella Kardys Journal: J Am Heart Assoc Date: 2019-02-19 Impact factor: 5.501